Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Negative plasma Epstein-Barr virus DNA nasopharyngeal carcinoma in an endemic region and its influence on liquid biopsy screening programmes

16 Sept 2019

Abstract excerpt

BACKGROUND: Epstein-Barr virus (EBV)-associated nasopharyngeal carcinoma (NPC) in endemic regions may have undetectable plasma EBV DNA. METHODS: We prospectively recruited 518 patients with non-metastatic NPC and measured their pre-treatment plasma EBV DNA. The stage distribution and prognosis between pre-treatment plasma EBV DNA-negative (0-20 copies/ml) and EBV DNA-positive (>20 copies/ml) patients following...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cervical Cancer and HPV Research
Share to Head and Neck Cancer Studies
Share to Viral-associated cancers and disorders

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31527689
DOI: 10.1038/s41416-019-0575-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Negative plasma Epstein-Barr virus DNA nasopharyngeal carcinoma in an endemic region and its influence on liquid biopsy screening programmesPMID 31527689Read ↗

Evaluation of plasma Epstein‐Barr virus DNA load to distinguish nasopharyngeal carcinoma patients from healthy high‐risk populations in Southern ChinaSemantic proximity Read ↗

Plasma Epstein-Barr virus DNA and risk of nasopharyngeal carcinoma in a prospective seropositive populationSemantic proximity Read ↗

Systematic comparison of plasma EBV DNA, anti‐EBV antibodies and miRNA levels for early detection and prognosis of nasopharyngeal carcinomaSemantic proximity Read ↗

Prevalence and significance of plasma Epstein-Barr Virus DNA level in nasopharyngeal carcinomaSemantic proximity Read ↗

Improved risk stratification of nasopharyngeal cancer by targeted sequencing of Epstein–Barr virus DNA in post-treatment plasmaSemantic proximity Read ↗

Relationship between pretreatment concentration of plasma Epstein‐Barr virus DNA and tumor burden in nasopharyngeal carcinoma: An updated interpretationSemantic proximity Read ↗

Plasma Epstein-Barr virus DNA for the prediction of treatment response and disease progression in non-keratinizing differentiated nasopharyngeal carcinomaSemantic proximity Read ↗

The Clinical Utility of Plasma Epstein–Barr Virus DNA Assays in Nasopharyngeal CarcinomaSemantic proximity Read ↗

Plasma Epstein–Barr Virus DNA and Risk of Future Nasopharyngeal CancerSemantic proximity Read ↗

Levels of plasma Epstein-Barr virus DNA prior and subsequent to treatment predicts the prognosis of nasopharyngeal carcinomaSemantic proximity Read ↗

Plasma Epstein–Barr virus DNA as an archetypal circulating tumour DNA markerSemantic proximity Read ↗

Plasma Epstein-Barr virus DNA as a biomarker for nasopharyngeal carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.